Anti-CEACAM5/CEA/CD66e Antibody (Tusamitamab ravtansine)
Catalog No.
F1089
Anti-CEACAM5/CEA/CD66e Antibody (Tusamitamab ravtansine)
Featured Products
Tusamitamab ravtansine (SAR408701) is a targeted ADC for CEACAM5-expressing tumor cells, consisting of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent maytansinoid DM4 via a cleavable linker. The average drug-to-antibody ratio (DAR) of tusamitamab ravtansine is 3.8.
144.52 kDa
Dry ice
2254086-60-5
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
SAR408701
100 mM Pro 20 mM Arg pH 5.0. No preservative!
P06731
Human,Cynomolgus [US9617345]
DM4
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
Human CEACAM5 / CEA / CD66e HEK293 Cell Line were stained Anti-CEACAM5 / CEA / CD66e Reference Antibody (Tusamitamab ravtansine) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, The EC50 is 0.61 ug/mL.
CEACAM5 / CEA / CD66e
Please avoid freeze-thaw cycles.